Our training program in pulmonary disease provides comprehensive research training for individuals with a serious commitment to a career in lung biology and biomedical research, particularly as it interfaces with clinical pulmonary medicine. Our primary premise has long been that lung disease represents major health problems in the U.S. and that progress toward improved understanding of the pathobiology of these diseases are required to make progress toward treatment and prevention. The program has a long history (30m years), training numerous physicians and scientists who have subscribed to this mission, and have become leaders in academic pulmonary medicine. The program is under new leadership and strives to maintain the previous scientific and training success, while adapting the next generation of researchers to new basic and translational science and technology. Recent changes have included expanded resources (recruitment of 24 new faculty members, and doubling the laboratory space). This has allowed us to broaden the scope of research questions related to lung biology, and attack the problems at the most basic and translational levels incorporating new cores in the Lung Biology ad Clinical Center Center and Harvard Medical Center. We have also enhanced our didactic program and further solidified program organization for oversight and mentoring of trainees. We identify trainees with a demonstrated interest in a research career. We also identify an environment where these individuals can pursue a problem of interest and in which creative and solid thinking combined with state-of-the-art technology is being used to pursue the problem, and provide them with the tools and mind-set to attack other problems in the future. Finally, we provide a prolonged period of support so that trainees are prepared to ultimately become a productive independent investigator, and the next leaders in pulmonary academics. Of the 38 trainees who have completed the program, 35 trainees in the last 10 years (92%) remain in academic medicine and research, 2 trainees are performing clinical research in industry, and only one trainee in the past decade is now in private practice. These trainees obtained 36 grant awards consisting of 20 NIH mentorship awards (K-and F Awards), 5 independent R-awards, 1 Project Leader on PPG, 2 Clinical Research Network grants, 3 Parker B. Francis awards, and 6 foundation awards (ATS/ALA, CF foundation), and have published 191 papers with their training grant mentors. As the Program Director of this training program, he will continue to work with the utmost enthusiasm and energy to ensure that the trainees of our training program will continue to excel and contribute significantly to the academic pulmonary community.

Public Health Relevance

Training program in pulmonary disease provides comprehensive research training for individuals with a serious commitment to a career in biomedical research focused on lung disease. Our primary goal is to train the next generation of physician scientist and scientist to become independent researchers in academic medicine to better understand the pathogenesis of lung disease and identify new therapeutic modalities in lung disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
5T32HL007633-28
Application #
8448255
Study Section
Special Emphasis Panel (ZHL1-CSR-M (O1))
Program Officer
Tigno, Xenia
Project Start
1985-07-01
Project End
2016-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
28
Fiscal Year
2013
Total Cost
$600,360
Indirect Cost
$39,492
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Desjardins, Christopher A; Cohen, Keira A; Munsamy, Vanisha et al. (2016) Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance. Nat Genet 48:544-51
Rahaghi, Farbod N; Wells, J Michael; Come, Carolyn E et al. (2016) Arterial and Venous Pulmonary Vascular Morphology and Their Relationship to Findings in Cardiac Magnetic Resonance Imaging in Smokers. J Comput Assist Tomogr 40:948-952
Bertero, Thomas; Oldham, William M; Cottrill, Katherine A et al. (2016) Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension. J Clin Invest 126:3313-35
Jiao, Junfang; King, Tonya S; McKenzie, Matthew et al. (2016) Vitamin D3 therapy in patients with asthma complicated by sinonasal disease: Secondary analysis of the Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma trial. J Allergy Clin Immunol 138:589-592.e2
Beitler, Jeremy R; Sands, Scott A; Loring, Stephen H et al. (2016) Quantifying unintended exposure to high tidal volumes from breath stacking dyssynchrony in ARDS: the BREATHE criteria. Intensive Care Med 42:1427-36
Putman, Rachel K; Hatabu, Hiroto; Araki, Tetsuro et al. (2016) Association Between Interstitial Lung Abnormalities and All-Cause Mortality. JAMA 315:672-81
Liu, Fei; Haeger, Christina Mallarino; Dieffenbach, Paul B et al. (2016) Distal vessel stiffening is an early and pivotal mechanobiological regulator of vascular remodeling and pulmonary hypertension. JCI Insight 1:
Colby, Jennifer K; Gott, Katherine M; Wilder, Julie A et al. (2016) Lipoxin Signaling in Murine Lung Host Responses to Cryptococcus neoformans Infection. Am J Respir Cell Mol Biol 54:25-33
Araki, Tetsuro; Putman, Rachel K; Hatabu, Hiroto et al. (2016) Development and Progression of Interstitial Lung Abnormalities in the Framingham Heart Study. Am J Respir Crit Care Med :
Ash, Samuel Y; Harmouche, Rola; Ross, James C et al. (2016) The Objective Identification and Quantification of Interstitial Lung Abnormalities in Smokers. Acad Radiol :

Showing the most recent 10 out of 144 publications